Parkinson's Disease and Melanoma: Mechanistically Linked via L-DOPA Treatment and Pheomelanin Carcinogenicity
Parkinson's disease (PD) and melanoma co-occur at higher-than-expected frequencies without a well-understood mechanism. L-DOPA, an intermediate in both neuronal dopamine synthesis and cutaneous melanin production, is commonly used to treat PD and has been suggested and also refuted to link these diseases. Prior studies show that red/blond biopigment (pheomelanin) exerts measurable carcinogenic activity that promotes melanomagenesis in humans and mice. We hypothesized that L-DOPA might boost pheomelanin production within red-haired or light-skinned genetic backgrounds, thereby elevating melanoma risk.
A clinical case is presented wherein a patient developed multiple new melanomas at a markedly increased rate shortly after initiating L-DOPA therapy for PD. Preclinical studies in red-haired, melanoma-prone mice (BrafV600E-inducible genetic model) revealed that L-DOPA significantly increased melanoma formation, together with increased pheomelanin. However, melanoma risk was reverted when pigment biosynthesis was genetically ablated (even with L-DOPA). Deep sequencing identified a "pheomelanin-associated mutational profile" within the tumors; this mutational pattern was also recognizable within human melanomas arising in red-haired individuals. These findings suggest that L-DOPA may elevate risk for melanoma at least in part independent of PD, in light-skinned individuals, via pheomelanin carcinogenesis.
BrafV600E-inducible red and red-albino mice were administered L-DOPA chow or control chow. Tumors from these mice were sequenced along with their matched control tissue. Mouse sequence data were submitted to NCBI SRA and are associated with BioProject PRJNA1450082.
- Type: Single Patient
- Archive: The database of Genotypes and Phenotypes (dbGaP)
